• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鉴定与早期膀胱癌进展相关的基因。

Identification of genes correlated with early-stage bladder cancer progression.

机构信息

Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center-Shreveport and Feist-Weiller Cancer Center, USA.

出版信息

Cancer Prev Res (Phila). 2010 Jun;3(6):776-86. doi: 10.1158/1940-6207.CAPR-09-0189. Epub 2010 May 25.

DOI:10.1158/1940-6207.CAPR-09-0189
PMID:20501863
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2881179/
Abstract

Transitional cell carcinoma (TCC) of the bladder ranks fourth in incidence of all cancers in the developed world, yet the mechanisms of its origin and progression remain poorly understood. There are also few useful diagnostic or prognostic biomarkers for this disease. We have combined a transgenic mouse model for invasive bladder cancer (UPII-SV40Tag mice) with DNA microarray technology to determine molecular mechanisms involved in early TCC development and to identify new biomarkers for detection, diagnosis, and prognosis of TCC. We have identified genes that are differentially expressed between the bladders of UPII-SV40Tag mice and their age-matched wild-type littermates at 3, 6, 20, and 30 weeks of age. These are ages that correspond to premalignant, carcinoma in situ, and early-stage and later stage invasive TCC, respectively. Our preliminary analysis of the microarray data sets has revealed approximately 1,900 unique genes differentially expressed (> or =3-fold difference at one or more time points) between wild-type and UPII-SV40Tag urothelium during the time course of tumor development. Among these, there were a high proportion of cell cycle regulatory genes and a proliferation signaling genes that are more strongly expressed in the UPII-SV40Tag bladder urothelium. We show that several of the genes upregulated in UPII-SV40Tag urothelium, including RacGAP1, PCNA, and Hmmr, are expressed at high levels in superficial bladder TCC patient samples. These findings provide insight into the earliest events in the development of bladder TCC as well as identify several promising early-stage biomarkers.

摘要

膀胱移行细胞癌(TCC)在发达国家的所有癌症发病率中排名第四,但它的起源和发展机制仍知之甚少。此外,这种疾病也几乎没有有用的诊断或预后生物标志物。我们将一种用于侵袭性膀胱癌的转基因小鼠模型(UPII-SV40Tag 小鼠)与 DNA 微阵列技术相结合,以确定早期 TCC 发展中涉及的分子机制,并确定用于检测、诊断和预后 TCC 的新生物标志物。我们已经确定了在 UPII-SV40Tag 小鼠及其年龄匹配的野生型同窝仔鼠的膀胱之间在 3、6、20 和 30 周龄时差异表达的基因。这些年龄分别对应于癌前病变、原位癌和早期和晚期侵袭性 TCC。我们对微阵列数据集的初步分析显示,在肿瘤发展过程中,野生型和 UPII-SV40Tag 尿路上皮之间差异表达(在一个或多个时间点差异 > 或 = 3 倍)的独特基因约有 1900 个。其中,细胞周期调控基因和增殖信号基因的比例较高,在 UPII-SV40Tag 膀胱尿路上皮中表达更强。我们表明,在 UPII-SV40Tag 尿路上皮中上调的几个基因,包括 RacGAP1、PCNA 和 Hmmr,在浅表性膀胱癌患者样本中表达水平较高。这些发现为膀胱癌的发展提供了最早事件的深入了解,并确定了几个有前途的早期生物标志物。

相似文献

1
Identification of genes correlated with early-stage bladder cancer progression.鉴定与早期膀胱癌进展相关的基因。
Cancer Prev Res (Phila). 2010 Jun;3(6):776-86. doi: 10.1158/1940-6207.CAPR-09-0189. Epub 2010 May 25.
2
Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder.膀胱浅表性移行细胞癌向浸润性移行细胞癌演变过程中进展相关基因的差异表达
Oncol Rep. 2001 Jan-Feb;8(1):9-15. doi: 10.3892/or.8.1.9.
3
Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification.膀胱中的基因表达:无论组织病理学分类如何,均存在一种常见的原位癌基因表达特征。
Cancer Res. 2004 Jun 1;64(11):4040-8. doi: 10.1158/0008-5472.CAN-03-3620.
4
Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma.在转基因小鼠中癌基因的尿路上皮特异性表达诱导了原位癌和浸润性移行细胞癌的形成。
Cancer Res. 1999 Jul 15;59(14):3512-7.
5
Highly invasive transitional cell carcinoma of the bladder in a simian virus 40 T-antigen transgenic mouse model.猿猴病毒40 T抗原转基因小鼠模型中的高侵袭性膀胱移行细胞癌
Am J Pathol. 2000 Sep;157(3):805-13. doi: 10.1016/S0002-9440(10)64594-4.
6
DNA copy number alterations and PPARG amplification in a patient with multifocal bladder urothelial carcinoma.一名多灶性膀胱尿路上皮癌患者的DNA拷贝数改变和PPARG扩增
BMC Res Notes. 2012 Oct 31;5:607. doi: 10.1186/1756-0500-5-607.
7
The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder.EphB2和EphB4受体激酶在正常膀胱组织和膀胱移行细胞癌中的差异表达。
PLoS One. 2014 Aug 22;9(8):e105326. doi: 10.1371/journal.pone.0105326. eCollection 2014.
8
p53-stabilizing agent CP-31398 prevents growth and invasion of urothelial cancer of the bladder in transgenic UPII-SV40T mice.p53 稳定剂 CP-31398 可预防转基因 UPII-SV40T 小鼠的膀胱癌生长和侵袭。
Neoplasia. 2013 Aug;15(8):966-74. doi: 10.1593/neo.13704.
9
Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma.核仁磷酸蛋白/B23 mRNA表达与膀胱癌患者临床结局的相关性
Urology. 2004 Oct;64(4):839-44. doi: 10.1016/j.urology.2004.05.020.
10
Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.膀胱移行细胞癌中Rb和p16肿瘤抑制基因以及CDK4的mRNA表达改变与肿瘤进展相关。
Anticancer Res. 2004 Mar-Apr;24(2B):1011-23.

引用本文的文献

1
The clinical value of the EpCAM biomarker and its association with immune cell infiltration in bladder cancer.EpCAM生物标志物在膀胱癌中的临床价值及其与免疫细胞浸润的关联。
Diagn Pathol. 2025 Aug 25;20(1):96. doi: 10.1186/s13000-025-01696-1.
2
The Expression Regulation and Cancer-Promoting Roles of RACGAP1.RACGAP1的表达调控及促癌作用
Biomolecules. 2024 Dec 24;15(1):3. doi: 10.3390/biom15010003.
3
RACGAP1 promotes lung cancer cell proliferation through the PI3K/AKT signaling pathway.RACGAP1 通过 PI3K/AKT 信号通路促进肺癌细胞增殖。

本文引用的文献

1
Cancer statistics, 2009.2009年癌症统计数据。
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.
2
Identification of the B-Raf/Mek/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion.鉴定B-Raf/Mek/Erk丝裂原活化蛋白激酶途径为全反式维甲酸在皮肤癌促进过程中的作用靶点。
Mol Cancer. 2009 May 11;8:27. doi: 10.1186/1476-4598-8-27.
3
Urothelial bladder cancer: biomarkers for detection and screening.尿路上皮膀胱癌:用于检测和筛查的生物标志物
Sci Rep. 2024 Apr 15;14(1):8694. doi: 10.1038/s41598-024-58539-0.
4
and in Muscle Invasive Bladder Cancer: A Functional and Clinical Evaluation Based on In Silico and In Vitro Data.以及在肌肉浸润性膀胱癌中:基于计算机模拟和体外数据的功能与临床评估
Cancers (Basel). 2019 Nov 21;11(12):1840. doi: 10.3390/cancers11121840.
5
Lambda-Carrageenan Enhances the Effects of Radiation Therapy in Cancer Treatment by Suppressing Cancer Cell Invasion and Metastasis through Racgap1 Inhibition.λ-角叉菜胶通过抑制Racgap1抑制癌细胞侵袭和转移,增强放射治疗在癌症治疗中的效果。
Cancers (Basel). 2019 Aug 16;11(8):1192. doi: 10.3390/cancers11081192.
6
Understanding the biology of urothelial cancer metastasis.了解尿路上皮癌转移的生物学机制。
Asian J Urol. 2016 Oct;3(4):211-222. doi: 10.1016/j.ajur.2016.09.005. Epub 2016 Sep 14.
7
Rac GTPase activating protein 1 promotes oncogenic progression of epithelial ovarian cancer.Rac GTP酶激活蛋白1促进上皮性卵巢癌的致癌进程。
Cancer Sci. 2018 Jan;109(1):84-93. doi: 10.1111/cas.13434. Epub 2017 Nov 22.
8
The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer.ERCC1和BRCA1的表达可预测尿路上皮癌铂类化疗的预后。
Onco Targets Ther. 2016 Jun 15;9:3465-71. doi: 10.2147/OTT.S101319. eCollection 2016.
9
Modelling bladder cancer in mice: opportunities and challenges.在小鼠中建立膀胱癌模型:机遇与挑战。
Nat Rev Cancer. 2015 Jan;15(1):42-54. doi: 10.1038/nrc3858.
10
Cross-contamination of a UROtsa stock with T24 cells--molecular comparison of different cell lines and stocks.urotsa 株与 t24 细胞的交叉污染——不同细胞系和细胞株的分子比较。
PLoS One. 2013 May 17;8(5):e64139. doi: 10.1371/journal.pone.0064139. Print 2013.
BJU Int. 2008 Nov;102(9 Pt B):1234-41. doi: 10.1111/j.1464-410X.2008.07965.x.
4
Biomarkers for detection and surveillance of bladder cancer.用于膀胱癌检测和监测的生物标志物。
Can Urol Assoc J. 2008 Jun;2(3):212-21. doi: 10.5489/cuaj.600.
5
The detection of genetic markers of bladder cancer in urine and serum.尿液和血清中膀胱癌基因标志物的检测。
Curr Opin Urol. 2008 Sep;18(5):499-503. doi: 10.1097/MOU.0b013e32830b86d1.
6
Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray.使用组织芯片分析膀胱癌中生物标志物的表达
Mol Carcinog. 2008 Sep;47(9):678-85. doi: 10.1002/mc.20420.
7
Potential of urinary biomarkers in early bladder cancer diagnosis.尿生物标志物在早期膀胱癌诊断中的潜力。
Expert Rev Anticancer Ther. 2007 Aug;7(8):1105-15. doi: 10.1586/14737140.7.8.1105.
8
Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy.多种生物标志物可改善膀胱切除术患者膀胱癌复发和死亡率的预测。
Cancer. 2008 Jan 15;112(2):315-25. doi: 10.1002/cncr.23162.
9
Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis.在预后不良的侵袭性人类乳腺癌、前列腺癌和肺癌中鉴定出一种整合的SV40 T/t抗原癌症特征。
Cancer Res. 2007 Sep 1;67(17):8065-80. doi: 10.1158/0008-5472.CAN-07-1515.
10
Bladder cancer biomarkers: current developments and future implementation.膀胱癌生物标志物:当前进展与未来应用
Curr Opin Urol. 2007 Sep;17(5):341-6. doi: 10.1097/MOU.0b013e3282c8c72b.